| Dr Reza David Seirafi, MD FACS | |
|
101 E Brunson St Ste 300, Enterprise, AL 36330-2500 | |
| (334) 393-3212 | |
| (334) 393-8747 |
| Full Name | Dr Reza David Seirafi |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 30 Years |
| Location | 101 E Brunson St Ste 300, Enterprise, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316904030 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 22745 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jackson Hospital & Clinic Inc | Montgomery, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Jackson Hospital And Clinic, Inc | 0547254153 | 139 |
News Archive
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
An international team of researchers, led by scientists at the University of California, San Diego School of Medicine, and the Eastern Hepatobiliary Surgery Hospital in China, say a human gene implicated in the development of leukemia also acts to prevent cancer of the liver.
As genetic testing for breast cancer has become more complex, evaluating a panel of multiple genes, it introduces more uncertainty about the results. But a new study finds that newer, more extensive tests are not causing patients to worry more about their cancer risk.
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 9 days ago
| Entity Name | Jackson Hospital And Clinic, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073264107 PECOS PAC ID: 0547254153 Enrollment ID: O20040414000971 |
News Archive
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
An international team of researchers, led by scientists at the University of California, San Diego School of Medicine, and the Eastern Hepatobiliary Surgery Hospital in China, say a human gene implicated in the development of leukemia also acts to prevent cancer of the liver.
As genetic testing for breast cancer has become more complex, evaluating a panel of multiple genes, it introduces more uncertainty about the results. But a new study finds that newer, more extensive tests are not causing patients to worry more about their cancer risk.
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 9 days ago
| Entity Name | Troy Surgical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356594238 PECOS PAC ID: 6406911023 Enrollment ID: O20090216000217 |
News Archive
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
An international team of researchers, led by scientists at the University of California, San Diego School of Medicine, and the Eastern Hepatobiliary Surgery Hospital in China, say a human gene implicated in the development of leukemia also acts to prevent cancer of the liver.
As genetic testing for breast cancer has become more complex, evaluating a panel of multiple genes, it introduces more uncertainty about the results. But a new study finds that newer, more extensive tests are not causing patients to worry more about their cancer risk.
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 9 days ago
| Entity Name | The Troy Hospital Health Care Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962733691 PECOS PAC ID: 1951436732 Enrollment ID: O20100611000387 |
News Archive
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
An international team of researchers, led by scientists at the University of California, San Diego School of Medicine, and the Eastern Hepatobiliary Surgery Hospital in China, say a human gene implicated in the development of leukemia also acts to prevent cancer of the liver.
As genetic testing for breast cancer has become more complex, evaluating a panel of multiple genes, it introduces more uncertainty about the results. But a new study finds that newer, more extensive tests are not causing patients to worry more about their cancer risk.
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Reza David Seirafi, MD FACS Po Box 240635, Montgomery, AL 36124-0635 Ph: (205) 435-0938 | Dr Reza David Seirafi, MD FACS 101 E Brunson St Ste 300, Enterprise, AL 36330-2500 Ph: (334) 393-3212 |
News Archive
The Food and Drug Administration (FDA) has announced the tentative approval of a co-packaged antiretroviral drug regimen manufactured by Aspen Pharmacare of South Africa for the treatment of HIV-1 infection in adults.
An international team of researchers, led by scientists at the University of California, San Diego School of Medicine, and the Eastern Hepatobiliary Surgery Hospital in China, say a human gene implicated in the development of leukemia also acts to prevent cancer of the liver.
As genetic testing for breast cancer has become more complex, evaluating a panel of multiple genes, it introduces more uncertainty about the results. But a new study finds that newer, more extensive tests are not causing patients to worry more about their cancer risk.
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 9 days ago
Mrs. Elisha M Collins, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 E Brunson St Ste 300, Enterprise, AL 36330 Phone: 334-393-3212 Fax: 614-656-3761 | |
Andrew A Duerr, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 1008 Boll Weevil Cir, Suite D, Enterprise, AL 36330 Phone: 334-347-0639 Fax: 334-347-1021 | |
Mr. Samuel Fleming Sawyer, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 101 E Brunson St, Suite 300, Enterprise, AL 36330 Phone: 334-393-3212 Fax: 334-393-4979 | |
William Kettunen, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 806 Glover Ave, Suite B, Enterprise, AL 36330 Phone: 334-489-4649 | |
Dr. William Daniel Sawyer, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 101 E Brunson St, Ste 300, Enterprise, AL 36330 Phone: 334-393-3212 Fax: 334-393-4979 | |
Dr. Sherry Lynn Roach, MD Surgery Medicare: Medicare Enrolled Practice Location: 101 E Brunson St, Ste 300, Enterprise, AL 36330 Phone: 334-393-3212 Fax: 334-393-4979 |